Morgan Stanley
CMPX icon

Morgan Stanley’s Compass Therapeutics CMPX Stock Holding History

Morgan Stanley’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Buy
735,186
+374,814
+104% +$1.11M ﹤0.01% 4979
2026
Q1 		$1.91M Sell
360,372
-4,873
-1% -$28.1K ﹤0.01% 4801
2025
Q4 		$1.96M Buy
365,245
+178,293
+95% +$823K ﹤0.01% 4825
2025
Q3 		$654K Sell
186,952
-61,797
-25% -$195K ﹤0.01% 5393
2025
Q2 		$647K Sell
248,749
-590,427
-70% -$1.22M ﹤0.01% 5336
2025
Q1 		$1.59M Buy
839,176
+460,624
+122% +$1.22M ﹤0.01% 4749
2024
Q4 		$549K Buy
378,552
+665
+0.2% +$1.1K ﹤0.01% 5381
2024
Q3 		$695K Buy
377,887
+209,971
+125% +$262K ﹤0.01% 5242
2024
Q2 		$168K Buy
167,916
+3,685
+2% +$5.38K ﹤0.01% 5750
2024
Q1 		$325K Sell
164,231
-63,759
-28% -$110K ﹤0.01% 5520
2023
Q4 		$356K Buy
227,990
+164,701
+260% +$285K ﹤0.01% 5461
2023
Q3 		$125K Sell
63,289
-55,607
-47% -$137K ﹤0.01% 5779
2023
Q2 		$378K Sell
118,896
-41,168
-26% -$129K ﹤0.01% 5356
2023
Q1 		$523K Buy
160,064
+95,566
+148% +$375K ﹤0.01% 5229
2022
Q4 		$324K Buy
64,498
+55,626
+627% +$222K ﹤0.01% 5452
2022
Q3 		$20K Buy
8,872
+8,259
+1,347% +$22.9K ﹤0.01% 6790
2022
Q2 		$2K Sell
613
-26,364
-98% -$57.2K ﹤0.01% 7573
2022
Q1 		$37K Buy
26,977
+9,504
+54% +$19.6K ﹤0.01% 6843
2021
Q4 		$56K Buy
+17,473
New +$57.9K ﹤0.01% 6756

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley's CMPX Position: Q2 2026 in Review

Morgan Stanley increased its Compass Therapeutics (CMPX) stake by 104% in Q2 2026, buying an estimated $1.11M and bringing the position to 735,186 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #4979.

Morgan Stanley first reported a position in CMPX in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.96M in Q4 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Morgan Stanley held 735,186 shares of Compass Therapeutics worth $1.61M as of Q2 2026.
  • Morgan Stanley bought 374,814 Compass Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Compass Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4979 holding.
  • Morgan Stanley first reported a position in Compass Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Morgan Stanley's Compass Therapeutics position peaked at $1.96M in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.